Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
This Phase I trial combines ADI-PEG 20 with docetaxel in patients with advanced solid tumors
with emphasis on castration resistant prostate cancer (CRPC). The investigators hypothesize
that the combination will result in greater tumor cytotoxicity with an acceptable toxicity
profile (i.e., manageable side effects) in cancer patients due to the unique mechanism of
action of ADI-PEG 20. The investigators also hypothesize that the combination of ADI-PEG 20
and docetaxel will result in enhanced tumor cell apoptosis in part due to autophagy and that
this will be particularly relevant in CRPC.